Table 1 Baseline characteristics of men with spinal metastases of prostate cancer at the time of spinal surgery.

From: Survival after spinal surgery for metastases in men with castration-sensitive vs castration-resistant prostate cancer: a nationwide register-based study

 

Castration-resistanta (n = 225)

Castration-sensitive (n = 81)

Age at surgery, year (median)

71.0(IQR 67.0–78.0)

70.0(IQR 66.0–76.0)

Age at surgery

  

 < 59 years

16 (7.1%)

7 (8.6%)

60–69

74 (32.9%)

30 (37.0%)

70–79

91 (40.4%)

28 (34.6%)

 > 80

44 (19.6%)

16 (19.8%)

Year of surgery

  

2010–2014

91 (40.4%)

21 (25.9%)

2015–2018

76 (33.8%)

36 (44.4%)

2019–2021

58 (25.8%)

24 (29.6%)

Time between prostate cancer diagnosis and spinal surgery (median), years

4.2 (2.0–8.3)

0 (0–0.1)

CCIb score 0

80 (35.6%)

21 (25.9%)

CCI score 1–3

50 (22.2%)

19 (23.5%)

CCI score 4–6

68 (30.2%)

28 (34.6%)

CCI score 7 and above

27 (12.0%)

13 (16.0%)

Spinal metastases as the first sign of malignancy

  

No

225 (100.0%)

18 (22%)

Yes

0 (0.0%)

63 (78%)

Frankelc classification

  

A

6 (2.7%)

5 (6.2%)

B

9 (4.0%)

6 (7.4%)

C

99 (44.0%)

39 (48.1%)

D

79 (35.1%)

23 (28.4%)

E

22 (9.8%)

5(6.2%)

Missing

10 (4.4%)

3 (3.7%)

  1. aCastration-resistant prostate cancer; Patients who were classified as having castration-resistant disease in PCBaSe at the time of spinal surgery, or who had received androgen deprivation therapy (ADT), i.e
  2. orchidectomy, GnRH agonist or antagonists or anti-androgen more than 3 months before the date of surgery.
  3. for spinal metastases were classified to be in castration-resistant state.
  4. bCharlson comorbidity index,
  5. cGrade A: complete lesion (paraplegia); grade B: only sensory function; grade C: motor function present but not of practical use (non-ambulatory); grade D: motor function present, sufficient to allow walking (ambulatory); grade E: no neurological symptoms.
Back to article page